Uxbridge, UK – 26 September 2022 – Immodulon Therapeutics Limited, the immuno-oncology company, announces the appointment of Joey Mason as a Non-Executive Director to the Board of Directors with immediate effect.
Joey Mason is a highly experienced life sciences financier and director with over 30 years of entrepreneurial and investment experience, including as head of the Life Science fund at M Ventures, the venture capital arm of Merck KGaA. Dr. Mason is co-founder and partner of Duplex Capital Partners, a venture capital investment firm focusing on biology and information technology, and is currently a Non-Executive Director of Axial3D Ltd., an award-winning medical imaging technology company.
Previously Dr. Mason led healthcare investments for over 10 years at Delta Partners, an early-stage focused venture capital firm based in Ireland, and has served as a Director or Observer on 20 public and private boards in the US and Europe over the past 25 years, including DNA Script SA, Plexium Inc., Neuravi Ltd and Genable Ltd. During this period, Dr. Mason served as Vice-chairman and Treasurer of InvestEurope (formerly EVCA), an association representing Europe’s private equity, venture capital and infrastructure sectors, as well as their investors. Dr. Mason began his career in investment banking at Morgan Stanley International and Technomark Consulting, before joining Biotrin plc, a biotechnology company based in Ireland specialised in diagnostic test manufacturing and development. Dr. Mason received his medical degree from Trinity College, Dublin, Ireland.
Andy Clarke, Chairman, commented:
“We are delighted to welcome Joey to our Board of Directors to support our strengthened senior leadership team. We look forward to the wealth of entrepreneurial and industry experience Joey will bring to Immodulon, as we continue to advance our lead product candidate, IMM-101, through clinical trials.”
Joey Mason said:
“I look forward to joining the Board of Directors at Immodulon and working with my new colleagues and the management team as the company continues to develop its promising clinical portfolio.”
About Immodulon Therapeutics
Immodulon Therapeutics Ltd. (London, UK) is a privately-owned, clinical-stage, immuno-oncology company primarily focused on the development of safe, effective, and novel treatments for cancer with an emphasis on pancreatic cancer. Its lead drug candidate, IMM-101, containing heat-killed Mycobacterium obuense which activates dendritic cells and other cells of the innate immune system predominantly via Toll-like receptor 2, has shown promise in early clinical trials. It is Immodulon’s vision that IMM-101 will become a backbone immunotherapy across multiple tumour types in combination with immune checkpoint inhibitors and any other standard-of-care treatment of the four major pillars of cancer therapy – immunotherapy, chemotherapy, radio/ablation therapy and surgery. For more information about Immodulon, please visit www.immodulon.com.